Windlas Biotech Limited has approved a share buyback worth up to Rs 47 crore, purchasing 4.7 lakh equity shares from existing investors. The buyback will occur at Rs 1,000 per share, representing 2.23% of the company’s equity. This buyback will be executed through the tender offer route, in compliance with Securities and Exchange Board of India (Sebi) regulations.
The total buyback size constitutes 9.8% of the company’s paid-up equity capital and free reserves, based on its latest audited financials as of March 31, 2025. The offer is open to all eligible public shareholders, while promoters and promoter group entities will not participate. Additionally, 15% of the buyback size is reserved for small shareholders.
April 24, 2026, has been set as the record date to determine shareholder eligibility. A buyback committee has been formed to oversee the process, with Fintellectual Corporate Advisors appointed as the merchant banker. The board may revise the buyback price upward while proportionately reducing the number of shares, without changing the overall buyback size.
